Year: 2021

Dlaboratory Sweden AB (publ) is announcing a patent-pending method for quantifying health status of a power grid. The ongoing energy transition is a fact and intermittent production, and consumption is increasing. The growing number of solar power installations and electrical cars that needs charging means increased challenges for grid operators. It has never been as important as now to have full control over your power grid system and the way forward is the use of smart grid technologies. The method developed by dLab aggregates disturbances seamlessly from individual power lines to a single KPI that describes the health of the entire power grid, a sharper and more versatile tool compared to current practice. In the everyday life of the grid operators this means knowing were in the grid investments are needed, being able to plan maintenance...

TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) — Exco Technologies Limited (TSX-XTC, OTCQX-EXCOF) a global supplier of innovative technologies servicing the die-cast, extrusion and automotive industries, today announced it has signed a definitive agreement to acquire the extrusion dies business of Halex Holdings GmbH (“Halex® Extrusion Dies”). The transaction is expected to close in the spring of 2022. “This acquisition will provide us with well-established and high-quality operations, manufacturing complex extrusion dies in Europe and will also allow us to better support our global customers”, said Nick Gnatyuk, Vice President and General Manager of Exco’s Extrusion Group. “We have been looking to expand into Europe for some time and we see Halex as the perfect fit”. Halex Extrusion Dies was founded in 1990 and operates four key manufacturing...

Ociperlimab adds innovative and complementary late-stage TIGIT inhibitor to an Oncology portfolio poised for growthTwo Phase III trials underway in non-small cell lung cancer and additional studies ongoing in a wide range of solid tumorsStrategic partnership expands opportunities for development with the PD-1 inhibitor tislelizumab, a potential bridge to synergistic combinations in the Novartis immunotherapy programInnovative market development collaboration also signed, expanding availability of select Novartis Oncology products in regions across China currently not covered by NovartisBasel, December 20, 2021 — Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology....

METTAWA, Ill., Dec. 20, 2021 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) today launched its 2022 Virtual Consumer Electronics Show (CES) Media Days presentation on Brunswick.com. The event, hosted by Brunswick’s Chief Executive Officer, Dave Foulkes, takes a closer look at the Company’s Next Wave strategy and highlights the future of recreational boating through its ACES (autonomy, connectivity, electrification, shared access) strategy, which will be on display at CES 2022 in Las Vegas, January 5-8, 2022. “CES 2022 will be an opportunity to bring together digital and physical elements of our ACES strategy with some of our latest award-winning and attention grabbing in-market products,” said Dave Foulkes, Brunswick Corporation CEO.  “Within our immersive and engaging exhibit, visitors will be transported from the convention...